Patents Assigned to The Rockefeller University
-
Patent number: 11325966Abstract: This invention relates to broadly neutralizing and potent anti-HIV-1 antibodies, kits, and methods of use thereof.Type: GrantFiled: December 22, 2017Date of Patent: May 10, 2022Assignees: The Rockefeller University, California Institute of TechnologyInventors: Michel Nussenzweig, Natalia T. Freund, Pamela J. Bjorkman, Louise Scharf
-
Patent number: 11325920Abstract: The present disclosure includes novel compounds useful as antimicrobial agents. The present disclosure further includes methods useful. The present disclosure further includes compositions and methods for treating or preventing a bacterial infection. The present disclosure further includes compositions and methods useful for preventing or reducing the growth or proliferation of microorganisms.Type: GrantFiled: January 24, 2019Date of Patent: May 10, 2022Assignee: The Rockefeller UniversityInventors: Sean Brady, James Peek
-
Publication number: 20220135985Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.Type: ApplicationFiled: October 18, 2021Publication date: May 5, 2022Applicants: The Broad Institute, Inc., Massachusetts Institute of Technology, The Rockefeller UniversityInventors: Feng Zhang, David Benjamin Turitz Cox, Luciano Marraffini, David Olivier Bikard, Wenyan Jiang, Neville Espi Sanjana
-
Patent number: 11312723Abstract: Pyranoyrazoles and pyrazolopyridines of formula I or formula II are disclosed: These compounds inhibit Coagulation Factor XIIa in the presence of thrombin and other coagulation factors. They are useful to treat autoimmune diseases.Type: GrantFiled: November 28, 2018Date of Patent: April 26, 2022Assignee: THE ROCKEFELLER UNIVERSITYInventors: Manish P. Ponda, Harold Selnick, Melissa Egbertson, Jan L. Breslow
-
Publication number: 20220120686Abstract: A multi-photon imaging system includes a laser module having a first channel for outputting a two-photon excitation laser pulse and a second channel for outputting a three-photon excitation laser pulse. The system further includes a first optical path for guiding the two-photon laser pulse from the first channel of the laser module and a second optical path for guiding the three-photon laser pulse from the second channel of the laser module. A microscope is also provided for simultaneously receiving the two-photon laser pulse from the first optical path and the three-photon laser pulse from the second optical path, and simultaneously, or with well controllable delays, delivering the two-photon laser pulse and the three-photon pulse to a target volume. The system further includes a photodetector configured to collect photons generated within the target volume in response to simultaneous excitation of the target volume by both the two-photon laser pulse and the three-photon laser pulse.Type: ApplicationFiled: January 30, 2020Publication date: April 21, 2022Applicant: The Rockefeller UniversityInventors: Alipasha VAZIRI, Siegfried WEISENBURGER
-
Patent number: 11299732Abstract: Provided are compositions and methods for cleaving a DNA sequence in a cell. The methods involve comprising introducing into a cell a recombinant vector containing a clustered regularly interspaced short palindromic repeats (CRISPR) system. The system includes a CRISPR RNA (crRNA) targeted to a DNA sequence in the cell that is operatively linked to a promoter; and CRISPR-associated enzymes (Cas) 10, Cas6, and at least one Csm protein. The Cas 10 cleaves the DNA sequence only during transcription of the DNA sequence that is operatively linked to the promoter. Also provided are recombinant vectors for modifying cells, cells that contain the recombinant vectors and modifications introduced by them, and kits that include the modified vectors.Type: GrantFiled: August 7, 2015Date of Patent: April 12, 2022Assignee: The Rockefeller UniversityInventors: Luciano Marraffini, Gregory Goldberg, Poulami Samai
-
Publication number: 20220095998Abstract: Hyperspectral dermoscopy images obtained in N wavelengths in the 350 nm to 950 nm range with a hyperspectral imaging camera are processed to obtain imaging biomarkers having a spectral dependence. Machine learning is applied to the imaging biomarkers to generate a diagnostic classification.Type: ApplicationFiled: July 7, 2021Publication date: March 31, 2022Applicant: THE ROCKEFELLER UNIVERSITYInventor: Daniel Gareau
-
Publication number: 20220054449Abstract: A treatment for inflammatory dermatoses, such as psoriasis and atopic dermatitis (eczema), is disclosed that utilizes topical administration of a halogenated xanthene, such as rose bengal, together with administration of one or more complementary targeted systemic dermatology therapies, preferably a therapy that addresses the inflammatory pathway and is other than an NSAID that is a COX-1 and/or COX-2 inhibitor. Examples of complementary targeted systemic therapeutic ingredients include: corticosteroids, including betamethasone dipropionate and fluocinonide; dithranol; vitamin D analogs, including calcipotriol; and retinoids, non-biologics including methotrexate, ciclosporin, hydroxycarbamide, and fumarates including dimethyl fumarate; as well as one or more biologics, including antibodies or paratope-containing antibody portions to TNF-?, antibodies to pro-inflammatory cytokines interleukin-12, interleukin-23 and interleukin-17, and TNF inhibitors.Type: ApplicationFiled: September 3, 2021Publication date: February 24, 2022Applicants: The Rockefeller University, Provectus Pharmatech, Inc.Inventors: James G. Krueger, Sandra Garcet, Jamie Singer, Eric A. Wachter
-
Patent number: 11225524Abstract: The present disclosure provides antibodies that specifically bind to Mer Tyrosine Kinase (MERTK) (e.g., human MERTK, or both human and mouse MERTK) and compositions comprising such antibodies, wherein said antibody agonizes MERTK signaling on endothelial cells. The present disclosure also provides methods for treating cancer, by administering an antibody that specifically binds to MERTK and agonizes MERTK signaling on endothelial cells.Type: GrantFiled: January 24, 2019Date of Patent: January 18, 2022Assignee: The Rockefeller UniversityInventors: Sohail Tavazoie, Nils Halberg, Masoud Tavazoie
-
Publication number: 20220002391Abstract: The present invention relates to broadly neutralizing anti-HIV-1 antibodies and isolated antigens. Also disclosed are related methods and compositions.Type: ApplicationFiled: September 10, 2021Publication date: January 6, 2022Applicants: The Rockefeller University, California Institute of TechnologyInventors: Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf, Johannes Scheid
-
Publication number: 20220002390Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.Type: ApplicationFiled: September 9, 2021Publication date: January 6, 2022Applicants: The Rockefeller University, California Institute of TechnologyInventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
-
Patent number: 11203739Abstract: Disclosed herein are compositions, systems, and methods for modulating proliferation, differentiation and pluripotency of cells.Type: GrantFiled: April 7, 2015Date of Patent: December 21, 2021Assignees: Memorial Sloan-Kettering Cancer Center, The Rockefeller UniversityInventors: Lydia W. S. Finley, Bryce W. Carey, Craig B. Thompson, C. David Allis
-
Patent number: 11199691Abstract: An imaging signal extraction apparatus comprising: an interface; a processing device, the processing device operatively coupled to the interface; and a computer readable medium comprising instructions that, when executed by the processing device, perform operations comprising: a) generating a two-dimensional image from imaging information obtained from the interface, thereby estimating ballistic component of the imaging information; b) generating a three-dimensional image by remapping the two-dimensional image; c) identifying a candidate object in the three-dimensional image; d) obtaining an estimated spatial forward model of the candidate object by mapping the three-dimensional image of the candidate object with a point-spread-function associated with the imaging apparatus; e) obtaining background-corrected data by using the estimated spatial forward model of the candidate object and estimated temporal components; and f) iteratively updating the estimated spatial forward model and estimated temporal componenType: GrantFiled: October 7, 2020Date of Patent: December 14, 2021Assignee: The Rockefeller UniversityInventors: Alipasha Vaziri, Tobias Noebauer, Oliver Skocek
-
Patent number: 11192889Abstract: Tetrahydronaphthyridines of formula are disclosed. These compounds selectively inhibit ?V?3 without activating the ?V?3 receptor. They are useful for treating osteoporosis, acute myelogenous leukemia, sickle cell disease, focal segmental glomerulosclerosis, fibrosis, supravalvular aortic stenosis associated with Williams syndrome, tumors expressing ?V?3, tumor metastasis, bone resorption, T-cell lymphoma, retinal disease, age-related macular degeneration, diabetic retinitis, and herpes simplex virus infection. They may also be used for inhibiting tumor angiogenesis.Type: GrantFiled: July 5, 2017Date of Patent: December 7, 2021Assignee: THE ROCKEFELLER UNIVERSITYInventors: Barry S. Coller, Marta Filizola, Michael Andrew Foley
-
Patent number: 11192893Abstract: Compounds of formula: are useful as antitumor agents. In these compounds, R10 is (a) (C1-C10) hydrocarbyl, (C1-C10)halohydrocarbyl, (C1-C6)hydroxyalkyl, or or R10 is (b) in which Q and A are linkers and Ar is optionally substituted monocyclic or bicyclic aryl or heteroaryl.Type: GrantFiled: May 18, 2018Date of Patent: December 7, 2021Assignee: The Rockefeller UniversityInventors: Tarun M. Kapoor, Moriteru Asano, Kazuyoshi Aso, Michael A. Foley, Yoshiyuki Fukase, Hideki Furukawa, Yashuhiro Hirata, Sachie Takashima, Tomohiro Okawa, Yuta Tanaka, Yayoi Yoshitomi
-
Patent number: 11180744Abstract: Acinetobacter lysin polypeptides and variants peptides with killing activity against gram negative bacteria. Methods for treating bacterial infections or bacterial colonization using Acintobacter lysin polypeptides.Type: GrantFiled: June 26, 2019Date of Patent: November 23, 2021Assignee: The Rockefeller UniversityInventors: Vincent Fischetti, Raymond Schuch, Rolf Lood, Benjamin Winer
-
Publication number: 20210332110Abstract: This disclosure provides novel broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.Type: ApplicationFiled: April 28, 2021Publication date: October 28, 2021Applicant: The Rockefeller UniversityInventors: Michel Nussenzweig, Davide F. Robbiani
-
Patent number: 11155799Abstract: The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including Streptococcus and Staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing Streptococcus suis derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.Type: GrantFiled: September 5, 2019Date of Patent: October 26, 2021Assignee: THE ROCKEFELLER UNIVERSITYInventors: Vincent A. Fischetti, Jonathan Schmitz, Daniel Gilmer, Chad Euler
-
Patent number: 11155605Abstract: The present invention relates to broadly neutralizing anti-HIV-1 antibodies and isolated antigens. Also disclosed are related methods and compositions.Type: GrantFiled: September 23, 2019Date of Patent: October 26, 2021Assignees: THE ROCKEFELLER UNIVERSITY, CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf, Johannes Scheid
-
Patent number: 11149081Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) broadly neutralizing antibodies having improved potency and breadth for neutralizing a range of HIV strains. Combinations of broadly neutralizing antibodies can also improve potency over a single antibody composition.Type: GrantFiled: December 7, 2017Date of Patent: October 19, 2021Assignees: THE ROCKEFELLER UNIVERSITY, CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: Ron Diskin, Anthony P. West, Michel C. Nussenzweig, Pamela J. Bjorkman